Prazer Therapeutics
PrivateLast Round
Series B
Apr 1, 2025
Est. Valuation
$79.1M
Total Funding Raised
$42.1M
Momentum
Top 10%
of companies Caplight tracks
Company Overview
Prazer Therapeutics operates in Healthcare & Life Sciences and is based in Seoul. Its latest recorded funding round was a Series B round in April 2025.
Prazer Therapeutics is a biotechnology company developing innovative therapeutics for various intractable diseases using its proprietary targeted protein degradation (TPD) platform called SPiDEM.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery
Business Model
B2B
Customer Profile
Revenue Share, Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Prazer Therapeutics Comparables
Compare Prazer Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Pin Therapeutics | 90% | |
| AUTOTAC Bio | 88% | |
| Amphista Therapeutics | 87% |
For institutional investors. Book with your work email.
Prazer Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Apr 1, 2025 | ||||
| Series A | Mar 8, 2021 | ||||
| Series A | Dec 23, 2020 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Prazer Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| K2 Investment Partners | Series B |
| Smilegate Investment | Series B, Series A |
| Premier Partners | Series B |
| QUAD Investment Management | Series B |
| Company K Partners | Series B, Series A |
| Kiwoom Investment | Series B, Series A |
| Mirae Asset Capital | Series B |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 27, 2026
Grew 19% QoQ, from 27 to 32 employees.
- Apr 26, 2026
Grew 32% QoQ from 19 to 25 employees.
For institutional investors. Book with your work email.
Prazer Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Prazer Therapeutics's valuation, stock price, and market status.
Is Prazer Therapeutics a public or private company?
Prazer Therapeutics is a private company.
What is the current stock price of Prazer Therapeutics?
Prazer Therapeutics is a private company, so its shares have no public market price. Caplight tracks Prazer Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Prazer Therapeutics worth (valuation)?
Prazer Therapeutics's valuation is estimated at $79.1M based on funding round data.
Can I buy Prazer Therapeutics stock?
Prazer Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Prazer Therapeutics's last funding round?
Prazer Therapeutics's most recent funding round was Series B on April 1, 2025.
Who are the main investors in Prazer Therapeutics?
Key investors in Prazer Therapeutics include Johnson & Johnson Innovation - JJDC, Inc..
Will Prazer Therapeutics IPO soon?
No public IPO plans have been announced for Prazer Therapeutics.
How can I track Prazer Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in Prazer Therapeutics's shares on secondary markets.